Immuron (IMRN) Interest Expenses (2017 - 2024)
Immuron's quarterly Interest Expenses came in at -$2.6 billion in Q4 2024, down 65623979.23% year-on-year from N/an in Q1 2024, and down 65623979.23% quarter-over-quarter from -$4007.0 in Q4 2023.
Immuron has reported Interest Expenses for 7 years, with the latest figure at -$2.6 billion in Q4 2024.
- For the quarter ending Q4 2024, Interest Expenses fell 65623979.23% year-over-year to -$2.6 billion; the trailing twelve-month figure through Sep 2025 stood at -$2.6 billion (down 65623979.23% YoY), and the FY2025 full-year result was $4734.6, down 4.71% from the prior year.
- Interest Expenses for Q4 2024 stood at -$2.6 billion, down from -$4007.0 in the prior quarter.
- The five-year high for Interest Expenses was -$9.5 in Q4 2021, with the low at -$2.6 billion in Q4 2024.
- Average Interest Expenses over 5 years is -$525.9 million, with a median of -$4007.0 recorded in 2023.
- Year-over-year, Interest Expenses jumped 88.04% in 2021 and slumped 65623979.23% in 2024.
- Tracing IMRN's Interest Expenses over 5 years: stood at -$79.4 in 2020, then jumped by 88.04% to -$9.5 in 2021, then sank by 47280.7% to -$4501.0 in 2022, then advanced by 10.98% to -$4007.0 in 2023, then tumbled by 65623979.23% to -$2.6 billion in 2024.
- The last three Interest Expenses figures came in at -$2.6 billion (Q4 2024), -$4007.0 (Q4 2023), and -$4501.0 (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2.63 Bn |
| Dec 31, 2024 | -2.63 Bn |
| Dec 31, 2023 | -4,007.00 |
| Dec 31, 2023 | -4,007.00 |
| Dec 31, 2022 | -4,501.00 |
| Dec 31, 2022 | -4,501.00 |
| Dec 31, 2021 | -9.50 |
| Dec 31, 2021 | -9.50 |
| Dec 31, 2020 | -79.40 |
| Dec 31, 2020 | -79.40 |
| Dec 31, 2019 | -23.46 |
| Dec 31, 2019 | -23.46 |
| Dec 31, 2017 | -2,935.78 |
| Dec 31, 2017 | -2,935.78 |